| REVIEW ARTICLE |
|
| Year : 2013 | Volume
: 3
| Issue : 4 | Page : 128-133 |
|
|
Vascular endothelial growth factor and its inhibitor in age-related macular degeneration
Xiying Wang1, Masahito Ohji2
1 Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan; Key Laboratory of Harbin Medical University Eye Center, Eye Hospital, First Affiliated Hospital, Harbin Medical University, Harbin, People's Republic of China
2 Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan
Correspondence Address:
Masahito Ohji
Department of Ophthalmology, Shiga University of Medical Science, Seta Tukinowacho, Otsu, Shiga 520-2192
Japan
 Source of Support: None, Conflict of Interest: None  | 3 |
DOI: 10.1016/j.tjo.2013.09.002
|
|
|
Intraocular angiogenesis is considered the leading cause for severe loss of vision, and contributes to many ocular diseases such as neovascular age-related macular degeneration, diabetic retinopathy, and retinopathy of prematurity, the main causes of blindness in developed countries.[1] An enormous body of work has demonstrated that vascular endothelial growth factor (VEGF) plays a prominent role as mediator in the procedure of pathological angiogenesis. This makes VEGF a potential target for the medical therapies of retinal angiogenesis and some clinical trials have proved the efficacy of anti-VEGF strategies. This review evaluates the role of VEGF in the pathogenesis of age-related macular degeneration and provides an overview of recent developments in therapeutic modalities.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
